We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial.
- Authors
Pandey, Ambarish; Kolkailah, Ahmed A; Cosentino, Francesco; Cannon, Christopher P; Frederich, Robert C; Cherney, David Z I; Dagogo-Jack, Samuel; Pratley, Richard E; Cater, Nilo B; Gantz, Ira; Mancuso, James P; McGuire, Darren K
- Abstract
This article discusses the results of a post-hoc analysis of the VERTIS CV trial, which examined the effects of the medication ertugliflozin on the risk of hospitalization for heart failure (HHF) in patients with type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular disease. The study found that ertugliflozin significantly reduced the risk of first HHF in the overall cohort of participants. However, the treatment effect was more pronounced in individuals with a pre-trial ejection fraction (EF) of less than 45% and attenuated in those with an EF greater than 60%. These findings contribute to the understanding of the efficacy of SGLT2 inhibitors in reducing the risk of HHF across different EF ranges.
- Subjects
VENTRICULAR ejection fraction; HEART failure; TYPE 2 diabetes; HOSPITAL care; SODIUM-glucose cotransporter 2 inhibitors
- Publication
European Heart Journal, 2023, Vol 44, Issue 48, p5163
- ISSN
0195-668X
- Publication type
Article
- DOI
10.1093/eurheartj/ehad639